Reduced frequencies and suppressive function of CD4+CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

Blood

Volumn 106, Issue 6, 2005, Pages 2018-2025

  Beyer, Marc ^b   Kochanek, Matthias ^b   Darabi, Kamruz ^b   Popov, Alexey ^b   Jensen, Markus ^b   Endl, Elmar ^b   Knolle, Percy A ^b   Thomas, Roman K ^b   Von Bergwelt Baildon, Michael ^b   Debey, Svenja ^b   Hallek, Michael ^b   Schultze, Joachim L ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUDARABINE; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEIN; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TREATMENT OUTCOME;

EID: 24744432528     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0642     Document Type: Article

References (78)

1. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
2. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801-805.
3. + regulatory T cells. Trends Immunol. 2004;25:374-380.
4. Jiang H, Chess L. An integrated view of suppressor T cell subsets in immunoregulation. J Clin Invest. 2004;114:1198-1208.
5. + regulatory T cells. Semin Immunol. 2004;16:89-98.
6. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol. 1998;160:1212-1218.
7. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol. 2003;3:223-232.
8. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
9. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823-832.
10. + T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol. 2003;171:5931-5939.
11. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336-344.
12. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med. 2004; 200:771-782.
13. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood. 2001;98: 2736-2744.
14. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, KnopJ, EnkAH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294.
15. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192:295-302.
16. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-310.
17. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311-323.
18. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142.
19. + T regulatory cells. Nat Immunol. 2003;4:337-342.
20. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
21. + regulatory T cells. Nat Immunol. 2003;4:330-336.
22. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol. 2002;169:2461-2465.
23. Takeda I, Ine S, Killeen N, et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulaton/T cells. J Immunol. 2004;172: 3580-3589.
24. + T cells in rats. Int Immunol. 2004;16:365-375.
25. high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-1253.
26. + regulatory T cells. Semin Immunol. 2004;16:89-98.
27. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol. 2000;18:423-449.
28. + regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004;199:971-979.
29. Crispin JC, Martinez A, Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun. 2003; 21:273-276.
30. + T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol. 2004;59:198-202.
31. de Kleer IM, Wedderburn LR, Taams LS, et al. CD4+CD25(bright) regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol. 2004;172:6435-6443.
32. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9:1144-1150.
33. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389-399.
34. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493-3499.
35. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112:1688-1696.
36. + regulatory T-cell levels in patients with melanoma. Clin Cancer Res. 2003; 9:2551-2559.
37. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
38. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
39. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61: 4766-4772.
40. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9: 4404-4408.
41. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003;98:1089-1099.
42. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.
43. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
44. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9:606-612.
45. + T regulatory cell function implicated in enhanced immune response by low dose cyclophosphamide. Blood. 2005;105:2862-2868.
46. Young JL Jr, Percy CL, Asire AJ, et al. Cancer incidence and mortality in the United States, 1973-77. Natl Cancer Inst Monogr. 1981:1-187.
47. O'Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995;85:307-318.
48. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052-1057.
49. Wendtner CM, Schmitt B, Bergmann M, Rohnisch T, Buhmann R, Hallek M. New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. Int J Hematol. 2001;73:32-38.
50. Lauria F, Foa R, Mantovani V, Fierro MT, Catovsky D, Tura S. T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset. Br J Haematol. 1983;54:277-283.
51. Foa R, Lauria F, Lusso P, et al. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1984;58:509-516.
52. Foa R, Fierro MT, Raspadori D, et al. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors. Blood. 1990;76:1349-1354.
53. Kunicka JE, Platsoucas CD. Defective helper function of purified T4 cells and excessive suppressor activity of purified T8 cells in patients with B-cell chronic lymphocytic leukemia. T4 suppressor effector cells are present in certain patients. Blood. 1988;71:1551-1560.
54. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984-989.
55. Kneitz C, Goller M, Wilhelm M, et al. Inhibition of T cell/B cell interaction by B-CLL cells. Leukemia. 1999;13:98-104.
56. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 2003;63:4497-4506.
57. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003; 44:383-389.
58. Scrivener S, Kaminski ER, Demaine A, Prentice AG. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulatioh. Br J Haematol. 2001;112:959-964.
59. + regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004; 20:107-118.
60. + T cell subsets to fludarabine. Biochem Pharmacol. 2003;66:2185-2191.
61. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, non-proliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000; 192:1213-1222.
62. + T helper cells. Eur J Immunol. 2004;34:1303-1311.
63. + T lymphocytes. Clin Cancer Res. 2004;10:828-839.
64. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002;196:255-260.
65. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001;193:1295-1302.
66. Wahl SM, Swisher J, McCartney-Francis N, Chen W. TGF-(beta): the perpetrator of immune suppression by regulatory T cells and suicidal T cells. J Leukoc Biol. 2004;76:15-24.
67. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194:629-644.
68. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5: 444-447.
69. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
70. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004;16:157-162.
71. Kim JD, Choi BK, Bae JS, et al. Cloning and characterization of GITR ligand. Genes Immun. 2003; 4:564-569.
72. Gurney AL, Marsters SA, Huang RM, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 1999;9:215-218.
73. Ji HB, Liao G, Faubion WA, et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol. 2004;172:5823-5827.
74. + T cells by producing CCL22. Eur J Immunol. 2002;32:1403-1413.
75. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194:847-853.
76. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002;62: 5267-5272.
77. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3:1011-1022.
78. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.